Engineered nucleic acids and methods of use thereof

Patent metadata

Field	Value
Publication number	US-9701965-B2
Application number	US-201414535484-A
Country	US
Kind code	B2
Filing date	Nov 7, 2014
Priority date	Oct 1, 2010
Publication date	Jul 11, 2017
Grant date	Jul 11, 2017

Abstract

Provided are compositions and methods for delivering biological moieties such as modified nucleic acids into cells to modulate protein expression. Such compositions and methods include the use of modified messenger RNAs, and are useful for production of proteins.

First claim

What is claimed is:

1. A method of producing in a cell a secreted immunoglobulin having a heavy chain and a light chain, comprising:
i) providing a target cell capable of protein translation;
ii) introducing into the target cell a composition comprising:
a) a first isolated nucleic acid, wherein the first isolated nucleic acid comprises a first translatable region having at least 95% identity to SEQ ID NO: 5 which encodes the same polypeptide as encoded by SEQ ID NO: 5, and
b) a second isolated nucleic acid, wherein the second isolated nucleic acid comprises a second translatable region having at least 95% identity to SEQ ID NO: 7 which encodes the same polypeptide as encoded by SEQ ID NO: 7; and

iii) substantially purifying the secreted immunoglobulin.

2. The method of claim 1 , wherein the target cell is a mammalian cell.

3. The method of claim 1 , wherein the first isolated nucleic acid and the second isolated nucleic acid are formulated in a lipid-based delivery molecule.

4. The method of claim 1 , wherein the first isolated nucleic acid and the second isolated nucleic acid in the composition are in a 1:1 ratio.

5. The method of claim 1 , wherein the first translatable region has at least 99% identity to SEQ ID NO: 5 and the second translatable region has at least 99% identity to SEQ ID NO: 7.

6. The method of claim 1 , wherein the first translatable region consists of the nucleic acid sequence set forth in SEQ ID NO: 5 and the second translatable region consists of the nucleic acid sequence set forth in SEQ ID NO: 7.

7. The method of claim 1 , wherein the first isolated nucleic acid comprises a first 5′ untranslated region (UTR) at the 5′ end of the first translatable region and a first 3′ UTR at the 3′ end of the first translatable region and the second isolated nucleic acid comprises a second 5′ UTR at the 5′ end of the second translatable region and a second 3′ UTR at the 3′ end of the second translatable region.

8. The method of claim 7 , wherein the first 5′ UTR and the second 5′ UTR each comprises a strong Kozak translational initiation signal.

9. The method of claim 7 , wherein the first isolated nucleic acid and the second isolated nucleic acid each independently comprises a poly A tail.

10. The method of claim 7 , wherein the first isolated nucleic acid and the second isolated nucleic acid each independently comprises a 5′ cap.

11. The method of claim 10 , wherein the 5′ cap is Cap 1.

12. The method of claim 1 , wherein the first isolated nucleic acid is an mRNA and the second isolated nucleic acid is an mRNA.

13. The method of claim 12 , wherein the first isolated nucleic acid and the second isolated nucleic acid comprise a nucleoside modification.

14. The method of claim 13 , wherein the nucleoside modification is pseudouridine.

15. The method of claim 13 , wherein the nucleoside modification is 1-methyl-pseudouridine.

16. The method of claim 1 further comprising measuring the binding of the secreted immunoglobulin to an antigen.

Assignees

• Modernatx Inc

Inventors

• Schrum Jason P
• Sieczkiewicz Gregory J
• Ejebe Kenechi
• Elbashir Sayda M

Classifications

• C12N15/102

  Mutagenizing nucleic acids · CPC title

• C12P21/00

  Preparation of peptides or proteins (single cell protein C12N1/00) · CPC title

• C12N2310/3341

  5-Methylcytosine · CPC title

• C07H21/02 Primary

  with ribosyl as saccharide radical · CPC title

• G01N33/559

  through a gel, e.g. Ouchterlony technique · CPC title